Marooned on Planet Earth

-ancient roman posca: water, red or white wine vinegar, honey, salt, herbs (coriander, mint, thyme)

-switchel: water, ginger, vinegar, sweetener, lemon, salt

-ayran: yogurt, water, salt, mint

-sees the reports of the heatwave in Europe-

Catch and kill is a surreptitious technique employed by newspapers and media outlets to prevent an individual from publicly revealing information damaging to a third party.

Using a legally enforceable non-disclosure agreement, the publisher purports to buy exclusive rights to "catch" the damaging story from the individual, but then "kills" the story for the benefit of the third party by preventing it from ever being published.

The individual with the information frequently does not realize that the tabloid intends to suppress the individual's story instead of publishing it.

Operation Mockingbird is an alleged large-scale program of the United States Central Intelligence Agency (CIA) that began in the early years of the Cold War and attempted to manipulate domestic American news media organizations for propaganda purposes.

According to author Deborah Davis, Operation Mockingbird recruited leading American journalists into a propaganda network and influenced the operations of front groups.

CIA support of front groups was exposed when an April 1967 Ramparts article reported that the National Student Association (NSA) received funding from the CIA.[1] In 1975, Church Committee Congressional investigations revealed Agency connections with journalists and civic groups.

About Us

$102,000,000 spent as of the end of March 2026, including his first term. That's 255 years of the president's $400,000 annual salary.

But who needs a $400,000 salary when you make $2B in your first year as president...

For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.

Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time.

Comic books are no strangers to pushing boundaries and blending fiction with reality in ways that spark intrigue. However, this sometimes leads to some pretty controversial takes. One of the most infamous examples came in 1988 when DC Comics revealed that the Joker, Batman’s arch-nemesis, had become the United Nations ambassador for Iran.